Therapeutic Nuclear Drug Market 2026 advancing with radiotherapy innovations

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Therapeutic Nuclear Drug Market Evolve From 2026 To 2030?

The market for therapeutic nuclear drugs has experienced significant expansion recently. Projections indicate a rise from $2.19 billion in 2025 to $2.51 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.5%. Historically, this expansion has been driven by factors such as the increasing incidence of cancer, the early integration of iodine-131 for thyroid conditions, a scarcity of specific oncology treatments, the expansion of nuclear medicine departments, and growing clinical approval for radiopharmaceuticals.

The therapeutic nuclear drug market is poised for significant expansion in the coming years. Projections indicate its value will reach $4.27 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.3%. This anticipated growth during the forecast period is driven by factors such as the creation of innovative therapeutic isotopes, the broadening application of precision oncology strategies, increased financial commitment to nuclear medicine infrastructure, a rise in clinical trials exploring radioligand therapies, and positive regulatory clearances for specific nuclear drugs. Key trends foreseen over this period encompass a greater acceptance of targeted radiopharmaceutical treatments, an expanded utilization of lutetium-177 and alpha-emitting isotopes, an increase in nuclear drug applications tailored for specific cancers, the broadening of combination therapies incorporating nuclear drugs, and an enhanced emphasis on safety dosimetry and adherence to regulatory standards.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19729&type=smp

What Key Drivers Are Influencing The Growth Of The Therapeutic Nuclear Drug Market?

The rising occurrence of cancer is anticipated to boost the expansion of the therapeutic nuclear drug market in the coming years. Cancer is a condition defined by the unrestrained multiplication and dissemination of abnormal cells. The widespread presence of cancer results from better detection and diagnosis, lifestyle choices, environmental factors, and genetic influences. Therapeutic nuclear drugs present a vital component in the fight against cancer, delivering targeted and efficient treatment options for individuals by shrinking tumor size, easing symptoms, and enhancing their quality of life. For example, in February 2024, the World Health Organization, a United Nations agency situated in Switzerland, projected that over 35 million new cancer cases would emerge by 2050, indicating a 77% increase when contrasted with the estimated 20 million cases in 2022. Thus, the growing prevalence of cancer is propelling the development of the therapeutic nuclear drug market.

Which Segment Areas Are Covered In The Therapeutic Nuclear Drug Market Analysis?

The therapeutic nuclear drug market covered in this report is segmented –

1) By Type: Radium-223, Lutetium-177, Iodine-131, Other Types

2) By Distribution Channel: Hospitals, Ambulatory Surgical Centers (ASCs), Cancer Research Institutes

3) By Application: Thyroid, Bone Metastasis, Lymphoma, Other Applications

What Key Developments And Trends Are Impacting The Therapeutic Nuclear Drug Market?

Leading companies within the therapeutic nuclear drug market are driving forward targeted radiotherapies, unveiling new multi-tumor treatment capabilities through developing clinical data. These initiatives aim to reinforce innovation streams, broaden therapeutic applications, and accelerate the adoption of next-generation radiopharmaceuticals. For example, in 2025, Actinium Pharmaceuticals, a US-based clinical-stage biopharmaceutical company, released new data for ATNM-400, its pioneering Actinium-225 radiotherapy, showcasing its multi-tumor potential, including in non-small cell lung cancer (NSCLC). These findings were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. ATNM-400 is engineered to deliver highly potent alpha-particle therapy with precise targeting, underscoring its promise as a transformative therapeutic platform across multiple solid tumors. This progress highlights the industry’s commitment to expanding the clinical utility of actinium-based radiotherapies to improve patient outcomes and extend market opportunities.

Which Global Companies Are Actively Competing In The Therapeutic Nuclear Drug Market?

Major companies operating in the therapeutic nuclear drug market are Bayer AG, Novartis International AG, Siemens Healthineers AG, Ipsen S.A., Jubilant DraxImage Inc., Mallinckrodt Pharmaceuticals PLC, The Bracco Group, Lantheus Medical Imaging Inc., Piramal Group, Curium Pharmaceuticals, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Eckert & Ziegler, Telix Pharmaceuticals Limited, International Isotopes inc., Orano SA, Q BioMed Inc., Molecular Targeting Technologies Inc, Medi-Radiopharma Co. Ltd., Actinium Pharmaceuticals, Fusion Pharmaceuticals

Read the full therapeutic nuclear drug market report here:

https://www.thebusinessresearchcompany.com/report/therapeutic-nuclear-drug-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Therapeutic Nuclear Drug Market?

North America was the largest region in the therapeutic nuclear drug market in 2025. The regions covered in the therapeutic nuclear drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Therapeutic Nuclear Drug Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19729&type=smp

Browse Through More Reports Similar to the Global Therapeutic Nuclear Drug Market 2026, By The Business Research Company

Sarcoma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/sarcoma-drugs-global-market-report

Drug Delivery Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report

Drug Infusion Systems Market Report 2026

https://www.thebusinessresearchcompany.com/report/drug-infusion-systems-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795